

**QUARTERLY REPORT ON CONSOLIDATED RESULTS FOR THE FOURTH QUARTER ENDED 31 DECEMBER 2009**

**THE FIGURES HAVE BEEN AUDITED**

**I. CONDENSED CONSOLIDATED INCOME STATEMENT**

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	Current year quarter 31/12/2009 RM'000	Preceding year corresponding quarter 31/12/2008 RM'000	Twelve months to 31/12/2009 RM'000	Twelve months to 31/12/2008 RM'000
1. (a) <b>Revenue</b>	<b>323,906</b>	<b>328,243</b>	<b>1,300,796</b>	<b>1,305,646</b>
(b) Cost of sales	(271,341)	(268,313)	(1,096,962)	(1,073,779)
(c) Gross profit	52,565	59,930	203,834	231,867
(d) Other income	8,585	2,085	13,292	3,120
(e) Expenses	(31,928)	(36,870)	(130,403)	(139,062)
(f) Finance costs	(1,146)	(1,590)	(4,467)	(6,267)
(g) Share of results of associate	(586)	941	(820)	941
(h) <b>Profit before income tax</b>	<b>27,490</b>	<b>24,496</b>	<b>81,436</b>	<b>90,599</b>
(i) Income tax	(5,372)	(6,574)	(19,709)	(29,190)
(j) <b>Profit for the year</b>	<b>22,118</b>	<b>17,922</b>	<b>61,727</b>	<b>61,409</b>
Attributable to:				
(k) Equity holders of the Company	21,914	17,789	60,191	60,031
(l) Minority interest	204	133	1,536	1,378
	<b>22,118</b>	<b>17,922</b>	<b>61,727</b>	<b>61,409</b>
2. Basic earnings per share attributable to equity holders of the Company	<b>20.48 sen</b>	<b>16.63 sen</b>	<b>56.26 sen</b>	<b>56.12 sen</b>

The condensed Consolidated Income Statement should be read in conjunction with the Annual Audited Financial Statements for the year ended 31 December 2008.

## II. CONDENSED CONSOLIDATED BALANCE SHEET

	<b>Audited As at end of current quarter 31/12/2009 RM'000</b>	<b>Audited As at preceding financial year end 31/12/2008 RM'000</b>
<b>ASSETS</b>		
1. Non-current assets		
Property, plant and equipment	277,515	257,804
Prepaid lease payments	3,033	3,116
Investments in associated companies	6,562	7,382
Goodwill	28,820	30,620
Other intangible assets	-	735
Deferred tax assets	3,904	3,246
	<b>319,834</b>	<b>302,903</b>
2. Current assets		
Inventories	228,067	162,210
Receivables	140,418	167,300
Amounts due from related companies	15,699	19,752
Amounts due from associated companies	1,789	3,091
Tax recoverable	8,030	1,607
Fixed deposits	60,534	58,300
Cash and bank balances	43,874	35,873
	<b>498,411</b>	<b>448,133</b>
3. Non-current assets held for sale	-	47,282
Total assets	<b>818,245</b>	<b>798,318</b>

### III. CONDENSED CONSOLIDATED BALANCE SHEET (CONT'D)

	<b>Audited As at end of current quarter 31/12/2009 RM'000</b>	<b>Audited As at preceding financial year end 31/12/2008 RM'000</b>
<b>EQUITY AND LIABILITIES</b>		
4. Equity attributable to equity holders of the Company		
Share capital	106,978	106,978
Reserves		
Share premium	22,447	22,447
Other reserves	(2,421)	(6,491)
Retained earnings	303,629	265,101
	430,633	388,035
5. Minority interest	15,703	14,167
Total equity	446,336	402,202
6. Non-current liabilities		
Long term borrowings	7,429	26,238
Deferred tax liabilities	3,131	3,236
Provision for defined benefit plan	2,449	1,474
	13,009	30,948
7. Current liabilities		
Payables	291,761	263,897
Amount due to immediate holding company	428	21
Amounts due to related companies	100	2,244
Amounts due to associated companies	4,571	2,112
Taxation payable	3,964	981
Dividend payable	-	6
Short term borrowings	39,539	41,722
Current portion of long term borrowings	18,537	54,185
	358,900	365,168
Total liabilities	371,909	396,116
Total equity and liabilities	818,245	798,318
8. <b>Net assets per share attributable to ordinary equity holders of the Company</b>	<b>RM4.03</b>	<b>RM3.63</b>

The condensed Consolidated Balance Sheet should be read in conjunction with the Annual Audited Financial Statements for the year ended 31 December 2008.

**III. CONDENSED CONSOLIDATED CASH FLOW STATEMENT**

	<b>Audited Twelve months to 31/12/2009 RM'000</b>	<b>Audited Twelve months to 31/12/2008 RM'000</b>
<b>Operating activities</b>		
Cash receipts from customers and related parties	1,365,439	1,410,607
Cash payments to suppliers	(1,151,237)	(1,034,445)
Cash payments to employees and for expenses	(108,243)	(157,896)
	<hr/>	<hr/>
Cash generated from operations	105,959	218,266
Interest paid	(3,398)	(3,956)
Profit on Murabahah Commercial Paper paid	(486)	(1,212)
Income taxes paid	(28,170)	(32,190)
Income taxes refund	840	1,148
Interest received	871	32
	<hr/>	<hr/>
<b>Net cash generated from operating activities</b>	<b>75,616</b>	<b>182,088</b>
<b>Investing activities</b>		
Proceeds from disposal of property, plant and equipment	159	389
Proceeds from disposal of non-current asset held for sale	55,541	350
Purchase of property, plant and equipment	(32,008)	(21,349)
	<hr/>	<hr/>
<b>Net cash generated from / (used in) investing activities</b>	<b>23,692</b>	<b>(20,610)</b>
<b>Financing activities</b>		
Proceeds from issuance of shares – exercise of share options	-	52
Dividend paid	(21,663)	(19,253)
Repayments of short term borrowings	(12,566)	(67,959)
Redemption of Murabahah Commercial Papers	(16,000)	-
Redemption of Murabahah Medium Term Notes	(15,000)	(15,000)
Repayment of term loan	(19,800)	(18,000)
Term loan interest paid	(918)	(2,183)
Profit on Murabahah Medium Term Notes paid	(1,388)	(2,142)
Fixed deposits released	-	8
	<hr/>	<hr/>
<b>Net cash used in financing activities</b>	<b>(87,335)</b>	<b>(124,477)</b>
	<hr/>	<hr/>
<b>Net change in cash and cash equivalents</b>	<b>11,973</b>	<b>37,001</b>
Currency translation differences	(1,738)	1,040
Net cash and cash equivalents as at beginning of financial year	94,173	56,132
	<hr/>	<hr/>
<b>Net cash and cash equivalents as at end of financial year</b> (a)	<b>104,408</b>	<b>94,173</b>
	<hr/>	<hr/>

**III. CONDENSED CONSOLIDATED CASH FLOW STATEMENT (CONT'D)**

	<b>Audited</b> <b>As at 31/12/2009</b> RM'000	<b>Audited</b> <b>As at 31/12/2008</b> RM'000
(a) <b>Cash and cash equivalents comprise the following amounts:</b>		
Cash and bank balances	43,874	35,873
Fixed deposits	60,534	58,300
Cash and cash equivalents	<u><b>104,408</b></u>	<u><b>94,173</b></u>

The condensed Consolidated Cash Flow Statement should be read in conjunction with the Annual Audited Financial Statements for the year ended 31 December 2008.

**IV. CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN TOTAL EQUITY**

← Equity attributable to equity holders of the Company →

	Share capital RM'000	Share premium RM'000	Exchange reserves RM'000	Retained earnings RM'000	Total RM'000	Minority interest RM'000	Total equity RM'000
<b>Twelve months to 31 December 2009 (audited)</b>							
Balance as at 1 January 2009	106,978	22,447	(6,491)	265,101	388,035	14,167	402,202
Currency translation differences, representing expenses recognised directly in equity	-	-	4,070	-	4,070	-	4,070
Profit for the year	-	-	-	60,191	60,191	1,536	61,727
Total recognised income and expense for the year	-	-	4,070	60,191	64,261	1,536	65,797
2008 final gross dividend of 27 sen, less taxation of 25%	-	-	-	(21,663)	(21,663)	-	(21,663)
Balance as at 31 December 2009	106,978	22,447	(2,421)	303,629	430,633	15,703	446,336

**IV. CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN TOTAL EQUITY (CONT'D)**

← Equity attributable to equity holders of the Company →

	Share capital RM'000	Share premium RM'000	Other reserves RM'000	Exchange reserves RM'000	Retained earnings RM'000	Total RM'000	Minority interest RM'000	Total equity RM'000
<b>Twelve months to 31 December 2008 (audited)</b>								
Balance as at 1 January 2008	106,963	22,410	3,428	(3,681)	220,551	349,671	12,789	362,460
Currency translation differences, representing expenses recognised directly in equity	-	-	-	(2,810)	-	(2,810)	-	(2,810)
Profit for the year	-	-	-	-	60,031	60,031	1,378	61,409
Total recognised income and expense for the year	-	-	-	(2,810)	60,031	57,221	1,378	58,599
2007 final 18 sen, tax exempt dividend	-	-	-	-	(19,253)	(19,253)	-	(19,253)
Employee share option scheme:								
- shares issued	15	37	-	-	-	52	-	52
- options lapsed	-	-	(550)	-	550	-	-	-
Employee equity scheme:								
- options granted	-	-	344	-	-	344	-	344
- options lapsed	-	-	(3,222)	-	3,222	-	-	-
Balance as at 31 December 2008	<u>106,978</u>	<u>22,447</u>	<u>-</u>	<u>(6,491)</u>	<u>265,101</u>	<u>388,035</u>	<u>14,167</u>	<u>402,202</u>

The condensed Statement of Changes in Total Equity should be read in conjunction with the Annual Audited Financial Statements for the year ended 31 December 2008.

**V. NOTES TO THE CONDENSED FINANCIAL STATEMENTS**

The notes to the condensed Financial Statements should be read in conjunction with the Annual Audited Financial Statements for the year ended 31 December 2008.

**1. Accounting policies and methods of computation**

The quarterly consolidated financial statements have been prepared by applying accounting policies and methods of computation consistent with those used in the preparation of the most recent audited financial statements of the Group and are in accordance with FRS 134, Interim Financial Reporting and Paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities").

**2. Audit report in respect of the 2008 financial statements**

The audit report on the Group's financial statements for the financial year ended 31 December 2008 was not qualified.

**3. Seasonal or cyclical factors**

The Group's operations are not subject to any significant seasonal or cyclical factors.

**4. Unusual items due to their nature, size or incidence**

There were no items affecting assets, liabilities, equity, net income, or cash flows that were unusual because of their nature, size or incidence in the current financial year ended 31 December 2009.

**5. Material changes in estimates used**

There were no other changes in estimates of amounts reported in prior interim periods of the current financial year or prior financial years that have a material effect in the current year.

**6. Debt and equity securities**

The Group did not undertake any other issuance and/or repayment of equity securities, share buy-backs, share cancellations, shares held as treasury shares and resale of treasury shares for the current financial year ended 31 December 2009 except for the redemption of RM16 million Murabahah Commercial Papers in February 2009 and RM15 million Murabahah Medium Term Notes in September 2009.

**7. Dividend**

No interim ordinary dividend has been declared for the financial year ended 31 December 2009 (2008: nil).

A final gross dividend of 27 sen less taxation of 25% (2007: 18 sen tax exempt dividend) on 106,977,788 (2007: 106,963,188) ordinary shares of RM1.00 each in respect of the financial year ended 31 December 2008 amounting to RM21,663,002 (2007: RM19,253,374) was approved by shareholders on 26 May 2009 and paid on 2 July 2009.

For the current financial year ended 31 December 2009, the Board of Directors recommend a final gross dividend of 27 sen, less taxation of 25% (2008: 27 sen gross dividend, less taxation of 25%) and a special gross dividend of 10 sen, less taxation of 25% (2008: nil) on ordinary shares in issue of 106,977,788 (2008: 106,977,788) for shareholders' approval at the forthcoming Annual General Meeting. The date of the Annual General Meeting and the book closure for the final dividend payment will be announced in due course.



8. **Segment information for the current financial year**

Segment information for the current financial year to 31 December 2009 is as follows:

	Pharmaceutical manufacturing and marketing RM'000	Pharmaceutical trading and distribution RM'000	Medical products and services RM'000	Other operations RM'000	Eliminations RM'000	Group RM'000
<b>Revenue</b>						
External revenue	1,942	1,284,402	14,452	-	-	1,300,796
Inter-segment revenue	138,574	21,990	-	34,684	(195,248)	-
Total revenue	140,516	1,306,392	14,452	34,684	(195,248)	1,300,796
<b>Results</b>						
Segment results	23,268	60,346	(2,336)	22,776	(2,164)	101,890
Unallocated corporate expenses						(16,036)
Profit from operations						85,854
Interest expense	-	(3,561)	-	(2,957)	2,051	(4,467)
Interest income	-	862	7	2,051	(2,051)	869
Share of results of associate						(820)
Profit before income tax						81,436
Income tax						(19,709)
<b>Profit for the year</b>						<b>61,727</b>
Attributable to:						
Equity holders of the Company						60,191
Minority interest						1,536
						61,727

9. **Non current assets held for sale**

In the second quarter 2009, Safire Pharmaceuticals (M) Sdn. Bhd. completed the transfer of control over the property, plant and equipment sold to Idaman Pharma Sdn. Bhd. Payments totalling RM34.0 million have been received, of the total consideration of RM35.0 million. As a result, the sale of the assets had been recognised in the second quarter 2009 with a gain on disposal of RM2.3 million.

In the fourth quarter 2009, PLSB completed the sale of two lots of vacant freehold land with carrying value of RM14.7 million. Total consideration of RM21.89 million was received and gain on disposal of RM7.19 million was recognised during the quarter.

## 10. Changes in the composition of the Group

There were no significant changes in the composition of the Group for the current year including business combinations, acquisitions or disposals of subsidiaries and long term investments, restructuring or discontinued operations except for the liquidation of one dominant subsidiary company of the Group, Pharmaniaga Trading (M) Sdn. Bhd. which has been completed during the year.

## 11. Contingent liabilities

There are no changes in the contingent liabilities as at the date of this announcement since the preceding financial year ended 31 December 2008 except as disclosed below:

	As at 01/01/2009	Increase	Decrease	As at 31/12/2009
	RM'000	RM'000	RM'000	RM'000
Bank performance and reimbursement bonds for concession business undertaken by a subsidiary company	45,000	-	-	45,000
Bank guarantees for projects and utilities undertaken by subsidiary companies	16,516	6,056	(3,212)	19,360
<b>Total</b>	<b>61,516</b>	<b>6,056</b>	<b>(3,212)</b>	<b>64,360</b>

## 12. Capital commitments

Authorised capital expenditure for the purchase of property, plant and equipment not provided for in the condensed consolidated financial statements were as follows:

	<b>As at 31/12/2009</b>
	RM'000
Authorised and contracted for:	
- acquisition of property, plant and equipment	<u>1,652</u>

13. **Income tax**

	Individual Quarter		Cumulative Quarter	
	Current year quarter <b>31/12/2009</b> RM'000	Preceding year corresponding quarter <b>31/12/2008</b> RM'000	Twelve months to <b>31/12/2009</b> RM'000	Twelve months to <b>31/12/2008</b> RM'000
Malaysian taxation				
- Current taxation	3,152	9,734	18,867	28,070
- Zakat	-	-	-	1,300
- Over provision in respect of prior years	(228)	(669)	(228)	(669)
- Deferred taxation	2,225	(2,611)	(220)	(864)
Sub-total	<u>5,149</u>	<u>6,454</u>	<u>18,419</u>	<u>27,837</u>
Foreign taxation				
- Current taxation	120	234	1,833	1,969
- Deferred taxation	103	(114)	(543)	(616)
Sub-total	<u>223</u>	<u>120</u>	<u>1,290</u>	<u>1,353</u>
Grand Total	<u><u>5,372</u></u>	<u><u>6,574</u></u>	<u><u>19,709</u></u>	<u><u>29,190</u></u>

The Group's effective tax rates for the current quarter and year are lower than the statutory tax rate of 25% mainly due to capital gains included in other income recognised during the financial year ended 31 December 2009 which is not subject to tax.

14. **Disposal of unquoted investments and/or properties**

There were no disposal of unquoted investments and/or properties in the current year except for the disposal of properties classified as non-current assets held for sale as detailed in Note 9.

15a) **Acquisitions and disposals of quoted securities**

There were no acquisitions and disposals of quoted securities in the current year.

15b) **Investments in quoted securities**

There were no investments in quoted securities other than securities in an existing subsidiary as at 31 December 2009.

16. **Status of corporate proposals announced but not completed as at the date of this announcement**

There are no corporate proposals announced by Phamaniaga Berhad ('Phamaniaga') but not completed as at the date of this announcement except for:

- (a) As at to date, Phamaniaga's public shareholding spread stands at 12.96%. The company had submitted an application for extension of the rectification of the public shareholding spread on 4 November 2009 for a period of 3 months from 5 November 2009. Bursa Malaysia Securities Berhad ("Bursa Securities") had through its letter dated 29 December 2009, rejected Phamaniaga's application for a further extension of time to comply with the Public Spread Requirement. In the same letter, Bursa Securities has also required Phamaniaga to rectify the shortfall in the public shareholding spread within 3 months from 29 December 2009, failing which enforcement action may be taken against Phamaniaga. UEM Group Berhad, the major shareholder of Phamaniaga is evaluating its options with regard to meeting the Public Spread Requirement within 3 months from 29 December 2009.
- (b) On 27 November 2008, the Company announced that one of its wholly-owned subsidiaries, Safire Pharmaceuticals (M) Sdn. Bhd. has entered into a sales and purchase agreement with Idaman Pharma Sdn. Bhd. (a third party) for the proposed disposal of land and asset for a total consideration of RM35.0 million. To date, a total of RM34.0 million has been received.

17. **Borrowings and debt securities**

Details of Group borrowings and debt securities as at 31 December 2009 are as follows:

	Long term borrowings			Short term borrowings		
	Secured	Unsecured	Total	Secured	Unsecured	Total
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
<b><u>Debt securities</u></b>						
Domestic						
- Murabahah Commercial Paper	-	-	-	-	13,891	13,891
- Murabahah Medium Term Notes	-	-	-	-	14,937	14,937
<b><u>Other borrowings</u></b>						
Domestic						
- Term loan	4,950	-	4,950	3,600	-	3,600
Foreign						
Indonesian Rupiah						
- Term loan	2,479	-	2,479	25,648	-	25,648
<b>TOTAL</b>	<b>7,429</b>	<b>-</b>	<b>7,429</b>	<b>29,248</b>	<b>28,828</b>	<b>58,076</b>

18. **Off Balance Sheet financial instruments**

There are no financial instruments with off-balance sheet risks as at the date of this announcement.

## 19. Material litigation

Since the preceding financial year ended 31 December 2008, there are no changes in material litigation as at the date of this announcement except for the following:

### (a) Demand by Siemens Financial Services GmbH (“Siemens”) for USD12.0 million

As at the date of this announcement, the Company confirms that no civil suit on the Company and its subsidiaries, Phamaniaga Logistics Sdn. Bhd. (“PLSB”) and Safire Pharmaceuticals (M) Sdn. Bhd. (“Safire”) has been filed by Siemens.

The Board of Directors of the Company upon consultation with the solicitors, is of the opinion that the positions of both PLSB and Safire are defensible.

### (b) Danaharta Urus Sdn. Bhd. vs Safri bin Nawawi (“Safri”) and Hamimah Binti Idruss (“Hamimah”) (by original action) Safri bin Nawawi & Anor vs Danaharta Urus Sdn. Bhd. and 6 others (action by counterclaim)

The Company announced on 18 January 2005, that Safri bin Nawawi and Hamimah binti Idruss, former directors of Safire, on 28 December 2004 have each commenced an action by way of Counterclaim against the Company in the legal suit originally filed by Danaharta Urus Sdn. Bhd. against them. The Company and Safire are named 4<sup>th</sup> Defendant and 3<sup>rd</sup> Defendant respectively in both Actions by Counterclaim and were served with the court papers on 11 January 2005. The Company had filed its Memorandum of Appearance in Court on 14 January 2005 and 18 January 2005 in respect of the Counterclaim.

The Company and Safire have both filed their respective defense to the Action by Counterclaim on 31 January 2005. The Company has further filed an application to strike out the Counterclaim on 3 March 2005.

The High Court has allowed the Company and Safire's striking out applications in relation to the counterclaim on 14 July 2009. Subsequently, Safri has filed the Notice of Appeal against the decision on 15 July 2009. The court has yet to fix any date for the case management on Safri's appeal.

The Board of Directors of the Company upon consultation with the solicitors is of the opinion that the positions of both the Company and Safire are defensible.

## 20. Comparison between the current quarter and the immediate preceding quarter

The Group's revenue for the fourth quarter 2009 recorded a drop of 1.8% from RM330.0 million in the immediate preceding quarter to RM323.9 million. This was mainly due to the lower sales registered by the Indonesian subsidiary.

Despite the lower revenue recorded in the current quarter 2009 against the immediate preceding quarter, the Group's profit before tax increased by RM18.1 million mainly due to higher gross profit, lower expenses and gain on disposal of two lots of land.

## 21. Review of performance for the current quarter and year

For the fourth quarter ended 31 December 2009, the Group registered a decline in revenue of 1.3% compared to the preceding year corresponding quarter. This was primarily due to the lower sales by the Indonesian subsidiary.

However, the Group's profit before tax registered a growth of 12.2% against the preceding year corresponding quarter. The growth was mainly due to lower operating expenses as well as the gain on disposal of two lots of land.

For the year under review, the Group maintained its previous year's revenue. The Group recorded profit before tax of RM81.4 million compared to last year of RM90.6 million, a drop of 10.2%. This was mainly attributed to lower gross profit margin, mitigated by lower expenses and gain on disposal of assets.

## 22. Prospects for 2010

Outlook of the Malaysian pharmaceutical industry is expected to improve. However, competition will remain tough particularly in the private market segment. The Phamaniaga Group will remain focused on strategies and initiatives to grow its market share in its core businesses.

## 23. Profit forecast

No commentary is made on any variance between actual profit from forecast profit, as it does not apply to the Group.

## 24. Earnings per share

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	Current year quarter <b>31/12/2009</b> RM'000	Preceding year corresponding quarter <b>31/12/2008</b> RM'000	Twelve months to <b>31/12/2009</b> RM'000	Twelve months to <b>31/12/2008</b> RM'000
Basic earnings per share				
Profit attributable to equity holders of the Company	21,914	17,789	60,191	60,031
Weighted average number of ordinary shares in issue ('000)	106,978	106,978	106,978	106,971
<b>Basic earnings per share</b>	<b><u>20.48 sen</u></b>	<b><u>16.63 sen</u></b>	<b><u>56.26 sen</u></b>	<b><u>56.12 sen</u></b>

## 25. Voluntary disclosure on Economic Profit ("EP") and headline Key Performance Indicators ("KPI")

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	Current year quarter <b>31/12/2009</b> RM'000	Preceding year corresponding quarter <b>31/12/2008</b> RM'000	Twelve months to <b>31/12/2009</b> RM'000	Twelve months to <b>31/12/2008</b> RM'000
<b>Economic Profit</b>	<b><u>16,749</u></b>	<b><u>13,072</u></b>	<b><u>44,385</u></b>	<b><u>49,286</u></b>

25 **Voluntary disclosure on Economic Profit (“EP”) and headline Key Performance Indicators (“KPI”) (continued)**

**Explanatory notes**

The EP statement is as prescribed under the GLC Transformation program, and is disclosed on a voluntary basis. EP is a measure of value created by a business during a single period reflecting how much return a business makes over its cost of capital.

The EP for the current quarter is recorded at RM16.7 million compared to RM13.1 million in the same period last year. The increase in EP performance for the current quarter was mainly due to the gain on disposal of two lots of land recognised in the final quarter of 2009.

The EP for the current year is RM44.4 million compared to RM49.3 million last year, mainly due to lower earnings for the year 2009.

As previously announced, the Group set its main headline Key Performance Indicators (“KPIs”) for 2009 of 6% Revenue Growth and 15% Return On Equity (“ROE”). Based on the year end results, the Board of Directors announced that the Group maintained its previous year’s revenue, whereas the ROE registered a 15% growth for 2009. Performance fell short of targets due to non-materialisation of sales from new markets, new hospital equipping projects and the planned acquisition of a company in Indonesia.

**By Order of the Board**

**Kuala Lumpur  
19 February 2010**

**WONG LEE LOO (MAICSA 7001219)  
NORHANA BINTI OTHMAN (LS0008547)  
Joint Secretaries**